Vanderbilt Personalized Medicine Core

描述(申请人提供)：分子医学、基因组学、蛋白质组学和生物信息学的进步加强了我们对疾病易感性、疾病表现以及对治疗的有益和不良反应的个体间差异的理解。范德比尔特大学医学中心将个性化健康和医疗保健作为研究目标，旨在开发方法学，为患者护理的临床决策提供新的信息-如基因、基因组或蛋白质组数据。凭借在临床药理学和药物发现、蛋白质组学、成像、遗传学和生物信息学方面的现有优势，我们相信Vanderbilt将对美国的个性化医疗保健产生影响。Vanderbilt在遗传和基因组科学、蛋白质组学和生物标记物发现、临床信息科学、BioVU(一个DNA生物库，已经超过54,000个样本)和其电子健康记录的合成衍生品方面进行了大量投资。实现这些投资的潜力需要继续招聘和投资于一支由年轻研究人员组成的多学科团队，该团队具有临床和基础药理学、质谱学、临床和基础遗传学、信息学以及遗传流行病学和生物统计学方面的专业知识。这一需求出现之际，经济环境和范德比尔特捐赠基金的减少迫使招聘放缓。因此，范德比尔特个性化医疗核心的目标是支持在这些领域拥有专业知识的初级教员的招聘和职业发展，他们可以利用范德比尔特的资源和环境来影响个性化医疗。临床药理学分部主任、临床和翻译科学家发展副院长南希·J·布朗博士将领导核心。DATS实验治疗研究所主任兼个性化医学助理副校长Dan M.Roden博士，生物医学信息学系教授兼主任Dan Masys博士，人类遗传学研究中心主任Jonathan Haines博士，以及Vanderbilt大学循证实践中心主任、医学与公共卫生研究所副主任Katherine E.Hartmann博士将监督项目的选择、开发和实施。该中心将利用现有的基础设施进行职业发展，并跟踪教师对个性化医学多学科研究的影响。

DESCRIPTION (provided by applicant): Advances in molecular medicine, genomics, proteomics and bioinformatics have enhanced our understanding of inter-individual variability in susceptibility to disease, in expression of disease, and in beneficial and adverse responses to therapies. Vanderbilt University Medical Center has prioritized personalized health and healthcare as a research goal, with the aim of developing methodologies to deliver new information - such as genetic, genomic, or proteomic data - to clinical decision-making in patient care. With existing strengths in Clinical Pharmacology and Drug Discovery, Proteomics, Imaging, Genetics and Bioinformatics, we believe Vanderbilt is poised to impact on personalized healthcare in the United States. Vanderbilt has made substantial investments in genetic and genomic science, in proteomics and biomarker discovery, in clinical information science, and in the creation of BioVU (a DNA biobank exceeding 54,000 samples already) and of the Synthetic Derivative of its electronic health record. Realizing the potential of these investments requires continued recruitment of and investment in a multidisciplinary team of young investigators with expertise in clinical and basic pharmacology, mass spectrometry, clinical and basic genetics, informatics, and genetic epidemiology and biostatistics. This need comes at a time when the economic climate and decreases in the Vanderbilt endowment have necessitated a slowing of hiring. The goal of the Vanderbilt Personalized Medicine Core, therefore, is to support the hiring and career development of junior faculty with expertise in these areas, who can exploit the resources and environment at Vanderbilt to impact on personalized medicine. Dr. Nancy J. Brown, Chief of the Division of Clinical Pharmacology and Associate Dean for Clinical and Translational Scientist Development will direct the Core. Dr. Dan M. Roden, Director of the Dates Institute for Experimental Therapeutics and Assistant Vice- Chancellor for Personalized Medicine; Dr. Dan Masys, Professor and Chair of the Department of Biomedical Informatics; Dr. Jonathan Haines, Director, Center for Human Genetics Research; and Dr. Katherine E. Hartmann, Director, Vanderbilt University Evidence-based Practice Center and Deputy Director, Institute for Medicine and Public Health will serve to oversee the selection, development and conduct of projects. The Core will leverage existing infrastructure for career development and for tracking the impact of faculty members on multidisciplinary research in personalized medicine.